Cargando…
PCC0208017, a novel small-molecule inhibitor of MARK3/MARK4, suppresses glioma progression in vitro and in vivo
Gliomas are the most common primary intracranial neoplasms among all brain malignancies, and the microtubule affinity regulating kinases (MARKs) have become potential drug targets for glioma. Here, we report a novel dual small-molecule inhibitor of MARK3 and MARK4, designated as PCC0208017. In vitro...
Autores principales: | Li, Fangfang, Liu, Zongliang, Sun, Heyuan, Li, Chunmei, Wang, Wenyan, Ye, Liang, Yan, Chunhong, Tian, Jingwei, Wang, Hongbo |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7016295/ https://www.ncbi.nlm.nih.gov/pubmed/32082974 http://dx.doi.org/10.1016/j.apsb.2019.09.004 |
Ejemplares similares
-
Anti-Colorectal Cancer Effects of a Novel Camptothecin Derivative PCC0208037 In Vitro and In Vivo
por: Li, Min, et al.
Publicado: (2022) -
Differential Signature of the Centrosomal MARK4 Isoforms in Glioma
por: Magnani, Ivana, et al.
Publicado: (2011) -
Evaluation of marking of peer marking in oral presentation
por: Steverding, Dietmar, et al.
Publicado: (2016) -
Bite mark evidence: bite mark analysis is not the same as bite mark comparison or matching or identification
por: Souviron, Richard, et al.
Publicado: (2017) -
Exploring cellular memory molecules marking competent and active transcriptions
por: Xin, Li, et al.
Publicado: (2007)